{"id":733,"date":"2023-08-17T07:55:24","date_gmt":"2023-08-17T07:55:24","guid":{"rendered":"https:\/\/theragent.com\/?page_id=733"},"modified":"2024-01-31T16:50:51","modified_gmt":"2024-01-31T16:50:51","slug":"t-cells-car-t","status":"publish","type":"page","link":"https:\/\/theragent.com\/your-products\/t-cells-car-t\/","title":{"rendered":"T-Cells: CAR-T"},"content":{"rendered":"
\n
<\/div>\n
\n
\n
Cell Types We Support<\/div>

T-Cells: CAR-T<\/h2>

Chimeric antigen receptor T-cells (CAR-T cells) are genetically modified T-cells with highly specific disease-targeting capability. The CAR binding domain is displayed on the surface of the T-cells to attach to the desired antigen. Upon binding to the antigen, the CAR-T cells are activated and become cytolytic, and the immune cascade follows to eliminate the diseased cells. <\/p>\n <\/div>\n <\/div><\/div>\n<\/header>\n\n

\n
\n
\n

The Approach<\/h3>\n

Currently commercialized CAR-T cells are all autologous, so the cells are sourced directly from the patient. Allogeneic CAR-T cells are in development and can help increase availability while driving down the cost of manufacturing. Several widely available instruments and protocols exist for the selection, expansion, and activation of the desired T-cell subpopulation. Theragent can work with existing CAR-T processes or develop new protocols depending on client needs. \u00a0<\/p>\n <\/div>\n <\/div>\n

\n
\n

The Challenge<\/h3>\n

Despite well-documented methods, the manufacturing and distribution of CAR-T cells has a number of significant challenges, including the lack of a common platform for production, the need for sourcing GMP grade vectors (i.e., lentivirus, transposon), the facility requirements for scaling out manufacturing, and cold-chain logistics & uniqueness of processes at the clinical site.<\/p>\n <\/div>\n <\/div>\n <\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n
\n
<\/div>\n\n\n\n

Theragent is the CDMO that can ensure the successful scale-up of your CAR-T therapy. <\/strong><\/p>\n\n\n\n

<\/div>\n<\/div>\n\n\n\n
\n
\n
\n